Volatility and Risk
Ceapro has a beta of 1.47, suggesting that its stock price is 47% more volatile than the S&P 500. Comparatively, ProMetic Life Sciences has a beta of 2.46, suggesting that its stock price is 146% more volatile than the S&P 500.
Valuation and Earnings
This table compares Ceapro and ProMetic Life Sciences”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Ceapro | $7.14 million | 1.86 | -$3.49 million | ($0.06) | -2.83 |
| ProMetic Life Sciences | $36.55 million | 3.49 | -$150.73 million | N/A | N/A |
Profitability
This table compares Ceapro and ProMetic Life Sciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Ceapro | -69.60% | -20.30% | -18.07% |
| ProMetic Life Sciences | -894.02% | -3,350.55% | -67.76% |
Institutional & Insider Ownership
0.1% of ProMetic Life Sciences shares are held by institutional investors. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
About Ceapro
Ceapro Inc., a biotechnology company, engages in the development and marketing of health and wellness products and technology relating to plant extracts in the United States, Germany, China, Canada, and internationally. The company is involved in the development of proprietary extraction technologies and the application of these technologies to the production, development, and commercialization of active ingredients, such as oat beta glucan and avenanthramides, which are derived from oats and other renewable plant resources for healthcare and cosmetic industries. It also offers natural active ingredients, including oat powder, oat oil, oat peptides, and lupin peptides to the personal care, cosmetic, medical, and animal health industries; anti-aging skincare products to the cosmeceutical industries; and veterinary therapeutic products, including an oat shampoo, an ear cleanser, and a dermal complex/conditioner. The company has a research collaboration with the Angiogenesis Foundation. The company was incorporated in 1997 and is headquartered in Edmonton, Canada.
About ProMetic Life Sciences
Prometic Life Sciences Inc. operates as a biopharmaceutical company with two drug discovery platforms that focuses on unmet medical needs in the field of fibrosis and orphan diseases. Its product pipeline includes PBI-4050, an orally active lead drug candidate for fibrosis; plasminogen, a biopharmaceutical for the treatment of congenital plasminogen deficiency; and intravenous immunoglobulin, a preparation of antibodies purified from plasma donations from healthy individuals. The company was founded in 1992 and is based in Laval, Canada.
Receive News & Ratings for Ceapro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ceapro and related companies with MarketBeat.com's FREE daily email newsletter.
